Drug Profile
Research programme: cyclodextrin-based therapeutics for Niemann-Pick type C disease - Okklo Life Sciences
Latest Information Update: 28 Sep 2020
Price :
$50
*
At a glance
- Originator Okklo Life Sciences
- Class Cyclodextrins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Niemann-Pick disease type C
Most Recent Events
- 28 Sep 2020 No recent reports of development identified for research development in Niemann-Pick-disease-type-C in Netherlands
- 02 Aug 2016 Research programme: cyclodextrin-based therapeutics for Niemann-Pick type C disease - Okklo is available for licensing as of 02 Aug 2016. http://www.okklo.com/
- 02 Aug 2016 Early research in Niemann-Pick disease type C in Netherlands (unspecified route)